


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 4

ATTY. DOCKET NO.
4-31157A/USN
APPLICATION NO.
09/480,236
APPLICANT
DIGAN ET AL.
FILING DATE
January 10, 2000RECEIVED
APR 17 2001
TECH CENTER GROUP 1644
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>AE</i>	AA	4,518,532	5/21/85	Umezawa et al.	260	404.5	
	AB	4,525,299	6/25/85	Umezawa et al.	260	112.5	
	AC	4,529,549	7/16/85	Umezawa et al.	260	404.5	
	AD	4,658,058	4/14/87	Umezawa et al.	564	159	
	AE	4,892,827	1/9/90	Pastan et al.	435	193	
	AF	4,946,778	8/7/90	Ladner et al.	435	69.6	
	AG	4,956,504	9/11/90	Takeuchi et al.	564	153	
	AH	4,983,328	1/8/91	Umezawa et al.	260	404.5	
	AI	5,162,581	11/10/92	Ikai et al.	564	157	
	AJ	5,458,878	10/17/95	Pastan et al.	424	260.1	
	AK	5,489,525	2/6/96	Pastan	435	7.23	
	AL	5,637,613	6/10/97	Renaut et al.	514	540	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	0 213 526	3/11/87	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AN	0 212 606	3/4/87	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AO	93/11162	6/10/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	0 765 866 B1	4/2/97	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	0 669 316 B1	8/30/95	Europe			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Anasetti et al., Transplantation, Vol. 54(5), "Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody," pp. 844-851 (1992)
	AS	BD PharMingen Technical Data Sheet, CD3: Purified Mouse Anti-Human CD3 Monoclonal Antibody for Immunohistochemistry (IHC) <i>Date? 5/09/2000</i>
<i>AE</i>	AT	Beverley et al., Eur. J. Immunol., Vol. 11, "Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody," pp. 329-334 (1981)

EXAMINER

Ewerdt

DATE CONSIDERED

4/14/01


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31157A/USN
APPLICATION NO.
09/480,236
APPLICANT
DIGAN ET AL.
FILING DATE
January 10, 2000

Sheet 2 of 4



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Burns et al., Journal of Immunology, Vol. 129(4), "Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen," pp. 1451-1457 (1982)
AB	Contreras et al., Transplantation, Vol. 65(9), "Peritransplant tolerance induction with anti-CD3-Immunotoxin," pp. 1159-1169 (1998)
AC	Early et al., Cell, Vol. 19, "An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: V _H D and J _H ," pp. 981-992 (1980)
AD	Gruber et al., J. Immunol., Vol. 152, "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>escherichia coli</i> ," pp. 5368-5374 (1994)
AE	Holliger et al., Proc. Nat. Acad. Sci., Vol. 90, "Diabodies": Small bivalent and bispecific antibody fragments," pp. 6444-6448 (1993)
AF	Kimata et al., Biochem. Biophys. Res. Commun., Vol. 191(3), "Expression of Non-ADP-Ribosylatable, Diphtheria Toxin-Resistant Elongation Factor 2 in <i>Saccharomyces cerevisiae</i> ," pp. 1145-1151 (1993)
AG	Knechtle et al., Transplantation, Vol. 63(1), "FN18-CRM9 Immunotoxin promotes tolerance in primate renal allografts," pp. 1-6 (1997)
AH	Kondo et al., J. Biol. Chem., Vol. 263(19), "Activity of immunotoxins constructed with modified <i>pseudomonas</i> exotoxin A lacking the cell recognition domain," pp. 9470-9475 (1988)
AI	Kostelny et al., J. Immunology, Vol. 148(5), "Formation of a bispecific antibody by the use of leucine zippers," pp. 1547-1553 (1992)
AJ	Kreitman et al., Blood, Vol. 83(2), "Recombinant Immunotoxins containing anti-tac(Fv) and derivatives of <i>pseudomonas</i> exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma," pp. 426-434 (1994)
AK	Kreitman et al., Cancer Biology, Vol. 6, "Targeting <i>Pseudomonas</i> exotoxin to hematologic malignancies," pp. 297-306 (1995)
AL	Mavroudis et al., Bone Marrow Transplantation, Vol. 17, "Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation 1996 pp 793-799
AM	Moehring et al., Somatic Cell Genetics, Vol. 5(4), "Codominant translational mutants of Chinese hamster ovary cells selected with diphtheria toxin," pp. 469-480 (1979)
AN	Neville et al., J. Immunother, Vol. 19(2), "A new reagent for the induction of T-cell depletion, anti-CD3-CRM9," pp. 85-92 (1996)

EXAMINER

EWoldt


DATE CONSIDERED

6/14/01

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31157A/USN
APPLICATION NO.
09/480,236
APPLICANT
DIGAN ET AL.
FILING DATE
January 10, 2000

Sheet 3 of 4

RECEIVED
APR 17 2001
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AB	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. and S. LeGrand Editors, pp. 491-495 (1994)
AC	Nikolic et al., Immunologic Research, Vol. 16(3), "Mixed Hematopoietic Chimerism and Transplantation Tolerance," pp. 217-228 (1997)
AD	Pack et al., Biochemistry, Vol. 31(6), "Miniantibodies: Use of amphiphatic helices to produce functional, flexibly linked dimeric F _v fragments with high avidity in <i>escherichia coli</i> ," pp. 1579-1584 (1992)
AE	Phan et al., J. Biol. Chem, Vol. 268(12), "Saccharomyces cerevisiae Elongation Factor 2," pp. 8665-8668 (1993)
AF	Sakano et al., Nature, Vol. 280, "Sequences at the somatic recombination sites of immunoglobulin light-chain genes," pp. 288-94 (1979)
AG	Salmeron, et al., Journal of Immunology, Vol. 147(9), "A conformational epitope expressed upon association of CD3- ϵ with either CD3- δ or CD3- γ is the main target for recognition by anti-CD3 monoclonal antibodies, pp. 3047-3052 (1991)
AH	Shalaby et al., J. Exp. Med., Vol. 175, "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the <i>HER2</i> protooncogene," pp. 217-225 (1992)
AI	Thomas et al., Transplantation, Vol. 64(1), "Preclinical studies of allograft tolerance in rhesus monkeys," pp. 124-35 (1997)
AJ	Thompson et al., J. Biol. Chem., Vol. 270(47), "An Anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood," pp. 28037-28041 (1995)
AK	Vallera et al., Blood, Vol. 88(6), "Anti-graft-versus host disease effect of DT ₃₉₀ -Anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 ϵ moiety of the T-cell receptor," pp. 2342-2353 (1996)
AL	Wu et al., Immunotechnology, Vol. 2, "Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers," pp. 21-36 (1996)
AM	
AN	

EXAMINER

Ewaldt

DATE CONSIDERED

6/14/01

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31157A/USN
APPLICATION NO.
09/480,236
APPLICANT
DIGAN ET AL.
FILING DATE
January 10, 2000

Sheet 4 of 4

RECEIVED
APR 17 2001
TECH CENTER 1000/2900
Group 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>AE</i>	AA	5,696,237	12/9/97	FitzGerald et al.	530	387.3	
	AB	5,863,745	1/26/99	Fitzgerald et al.	435	7.21	
	AC	5,869,734	2/9/99	Wang et al.	560	25	
	AD	5,489,525	2/6/96	Pastan	435	7.23	
<i>AE</i>	AE	6,103,235	8/15/00	Neville et al.	424	183.1	
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

Ew

DATE CONSIDERED

6/14/01

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.